Niranjan Sardesai

Niranjan Sardesai is the founder, president and CEO of Geneos Therapeutics, a Plymouth Meeting, Pennsylvania biotech building personalized DNA-based cancer vaccines that are custom-designed to each patient's own tumor mutations. A Caltech-trained chemist with a Wharton MBA, he spent years as COO helping build Inovio Pharmaceuticals into a Phase III immunotherapy company before spinning out Geneos in 2016. Under his leadership Geneos published a landmark Nature Medicine paper in 2024 showing its neoantigen vaccine drove complete responses in advanced liver cancer, with some patients reaching multi-year, recurrence-free survival.